« Previous | Next » | All Messages |  ADH Message Board Home | recommend post |  Ignore Poster

Adherex Technologies Announced Third Quarter

Adherex Technologies Inc. (AMEX:ADH Stock Message Boards) (TSX:AHX), a biopharmaceutical company with many oncology products under development, reported financial results for the third quarter ended September 30, 2007. Unless otherwise indicated, the amounts included in this press release are in U.S. dollars.

Financials Updated

The net loss for the quarter ended September 30, 2007 was $3.2 million, or $0.02 loss per share, compared to a net loss of $4.6 million, or $0.09 loss per share, for the quarter ended September 30, 2006. Operating expenses for the quarter ended September 30, 2007 totaled $3.5 million as compared to $4.8 million in the same period in 2006.

The net loss for the nine-month period ended September 30, 2007 was $10.3 million, or $0.09 loss per share, compared to a net loss of $11.7 million, or $0.25 loss per share, for the nine-month period ended September 30, 2006.

Cash, cash equivalents and short-term investments totaled $18.4 million as of September 30, 2007, compared to $5.7 million as of December 31, 2006, with a corresponding increase in working capital of $15.5 million. The increased cash balance reflects the net proceeds of $23.2 million from the equity offering completed in February 2007 offset by expenditures to fund operations.

The selected consolidated financial data presented below are derived from our consolidated financial statements prepared under United States generally accepted accounting principles and are not complete. Specifically, they exclude the accompanying footnotes, which are an integral part of the consolidated financial statements. The complete consolidated financial statements for the quarter ended September 30, 2007 and management's discussion and analysis of financial condition and results of operations will be made available on Form 10-Q via our website at www.adherex.com.

Corporate Update

During and subsequent to the quarter ended September 30, 2007, Adherex's accomplishments of note included:

- The launch of a Phase III trial of sodium thiosulfate (STS) in children 
  with hepatoblastoma (liver cancer) with our collaborative partner, the 
  International Childhood Liver Tumour Strategy Group (known as SIOPEL), a 
  multi-disciplinary group of specialists under the umbrella of the 
  International Society of Pediatric Oncology (SIOP). The trial was opened 
  for patient enrollment in the United Kingdom and additional SIOPEL 
  centers in up to 33 further countries are also expected to participate.

- Continuation of the ongoing clinical trials, including:

  - The Phase I clinical trial of ADH-1 in combination with three separate 
    chemotherapy agents (docetaxel, capecitabine or carboplatin), which is 
    currently accruing the highest dose level cohort of patients. The 
    Company continues to expect this trial to complete patient enrollment 
    by the end of 2007.

  - The Phase I clinical trial of systemic ADH-1 in combination with 
    isolated limb infusion melphalan for the treatment of melanoma, which 
    is currently accruing the highest projected dose level cohort of 
    patients. The Company continues to expect this trial to complete 
    patient enrollment by the end of 2007.

  - The Phase I clinical trial of eniluracil in combination with 5-FU in 
    North America, which is currently enrolling patients at a dose of 160mg 
    of 5-FU. This trial has required additional dose cohorts due to the 
    ability to administer substantially higher doses of 5-FU than initially 
    anticipated. Further dose escalations may be required to determine the 
    maximum tolerated dose (MTD) of 5-FU. However, the Company continues to 
    expect this trial to complete patient enrollment by the end of 2007. A 
    Phase II clinical trial in breast cancer is planned once the MTD has 
    been determined.

  - The Phase I/II clinical trial of eniluracil in combination with 5-FU in 
    hepatocellular cancer in Asia. This trial is being amended to permit 
    more rapid dose escalations based upon the results of the ongoing Phase 
    I trial in North America. As a result, we would expect to complete 
    patient enrollment in the Phase I portion of this trial approximately 
    three to six months following completion of the North American Phase I 
    trial.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.